Identification and biochemical analyses of selective CB₂ agonists

Area of Science:

• Pharmacology
• Immunology
• Medicinal Chemistry

Background:

• Cannabinoid CB1 receptors are in the brain, mediating psychoactive effects of marijuana's Δ9-tetrahydrocannabinol.
• Cannabinoid CB2 receptors are in immune cells, making them a target for immune-related diseases.
• Selective CB2 receptor agonists are needed for therapeutic development.

Purpose of the Study:

• To identify and characterize small molecules that selectively bind to the cannabinoid CB2 receptor.
• To evaluate the potential of these molecules as therapeutics for immune-related maladies and pain.

Main Methods:

• Radioligand competition binding assays to determine affinity for CB2 receptors.
• GTPγS binding assays to assess G-protein coupling potency.
• Immunoblotting to analyze ERK1/2 and MEK phosphorylation.
• Cell proliferation assays using Jurkat cells.

Main Results:

• Three compounds (ABK5, ABK6, ABK7) selectively bound to CB2 receptors, with no detectable binding to CB1 receptors up to 10 μM.
• Compounds increased ERK1/2 and MEK phosphorylation in a Gi/o-dependent manner.
• ABK5 inhibited Jurkat cell proliferation.

Conclusions:

• ABK5, ABK6, and ABK7 are novel cannabinoid CB2 receptor agonists.
• These compounds demonstrate selective CB2 receptor activation and anti-proliferative effects.
• They hold promise for developing therapeutics to treat inflammation and associated pain.